Table 2.

Prognostic Factors for Overall Survival

Factor	n	Hazard Ratio (95% CI)	P
Sex, Male versus Female	41	1.31 (0.54–3.17)	.55
Type of Perioperative Chemotherapy
Adjuvant versus neoadjuvant	41	0.85 (0.38–1.88)	.68
GC versus others	41	1.21 (0.56–2.63)	.62
Number of Cycles of Perioperative Chemotherapy, Continuous	41	1.20 (0.94–1.53)	.15
Metastases at Recurrence, Visceral versus Nonvisceral	41	1.55 (0.74–3.27)	.25
Time From Last Perioperative Chemotherapy to First-Line Chemotherapy
≥52 Weeks versus <52 weeks	41	0.58 (0.28–1.24)	.16
≥78 Weeks versus <78 weeks	41	0.45 (0.20–0.99)	.048
≥104 Weeks versus <104 weeks	41	0.44 (0.17–1.16)	.097
Log-transformation	41	0.75 (0.51–1.09)	.13
Age, Years	41	0.96 (0.91–1.01)	.14
ECOG Performance Status, 1–2 versus 0	41	4.96 (1.80–13.68)	.002
Hemoglobin, Anemic (<LLN) versus Nonanemic	40	1.61 (0.78–3.30)	.20
Leukocyte Count, ≥ULN versus <ULN	39	2.82 (1.27–6.23)	.011
Creatinine Clearance, ≥60 versus <60 ml/minute	39	1.49 (0.59–3.75)	.39
Albumin per Unit	34	0.55 (0.26–1.16)	.12
Type of First-Line Chemotherapy, GC versus Other	41	0.81 (0.39–1.67)	.57
Dose of Cisplatin, ≥70 versus <70 mg/m2 per Cycle	41	0.86 (0.26–2.87)	.81
Multivariate Model
ECOG performance status, 1–2 versus 0	41	4.56 (1.66–12.52)	.003
Time from last perioperative chemotherapy to first-line chemotherapy, ≥78 weeks versus <78 weeks	41	0.48 (0.21–1.07)	.072

Abbreviations: ECOG = Eastern Cooperative Oncology Group; GC = gemcitabine and cisplatin; LLN = lower limit of normal; ULN = upper limit of normal.